Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer
- 1 October 1999
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 25 (5) , 271-277
- https://doi.org/10.1053/ctrv.1999.0132
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersOncogene, 1999
- Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugsOncogene, 1998
- Treatment of Breast CancerNew England Journal of Medicine, 1998
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.Journal of Clinical Oncology, 1998
- HER‐2/ neu Signal Transduction in Human Breast and Ovarian CancerThe International Journal of Cell Cloning, 1997
- Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.Journal of Clinical Oncology, 1996
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996
- Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer researchBreast Cancer Research and Treatment, 1995
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987